COPD in chronic heart failure: Less common than previously thought?  by Minasian, Armine G. et al.
at SciVerse ScienceDirect
Heart & Lung 42 (2013) 365e371Contents lists availableHeart & Lung
journal homepage: www.heartandlung.orgCOPD in chronic heart failure: Less common than previously thought?
Armine G. Minasian, MD, PhD(c) a,*, Frank J.J. van den Elshout, MD, PhD a,
P.N. Richard Dekhuijzen, MD, PhD b, Petra J.E. Vos, MD, PhD a, Frank F. Willems, MD, PhD c,
Paul J.P.C. van den Bergh, MD c, Yvonne F. Heijdra, MD, PhD b
aDepartment of Pulmonary Diseases, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands
bDepartment of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands
cDepartment of Cardiology, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlandsa r t i c l e i n f o
Article history:
Received 17 January 2013
Received in revised form
29 June 2013
Accepted 1 July 2013
Keywords:
Chronic heart failure
Chronic obstructive pulmonary disease
Prevalence
Fixed ratio
Lower limit of normalAbbreviations: ABHR, aspeciﬁc bronchial hyperre
converting enzyme inhibitor; ARB, angiotensin recep
ican Thoracic Society/European Respiratory Society; B
coronary artery bypass grafting; COPD, chronic obstru
cardiac resynchronization therapy; CS, current smok
expiratory volume in 1 s to forced vital capacity; FS, fo
Initiative for Chronic Obstructive Lung Disease; HF, h
cardioverter deﬁbrillator; LLN, lower limit of normal;
fraction; LVSD, left ventricular systolic dysfunction; M
Heart Failure Questionnaire; MRC, modiﬁed Medica
scale; NS, non-smokers; NT-pro-BNP, N-terminal pro-
New York Heart Association; PCI, percutaneous coro
monary function tests; PY, pack-years.
0147-9563/$ e see front matter  2013 Elsevier Inc.
http://dx.doi.org/10.1016/j.hrtlng.2013.07.002a b s t r a c t
Background: Using a ﬁxed ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/
FVC) < 0.70 instead of the lower limit of normal (LLN) to deﬁne chronic obstructive pulmonary disease
(COPD) may lead to overdiagnosis of COPD in elderly patients with heart failure (HF) and consequently
unnecessary treatment with possible adverse health effects.
Objective: The aim of this study was to determine COPD prevalence in patients with chronic HF according
to two deﬁnitions of airﬂow obstruction.
Methods: Spirometry was performed in 187 outpatients with stable chronic HF without pulmonary
congestion who had a left ventricular ejection fraction <40% (mean age 69  10 years, 78% men). COPD
diagnosis was conﬁrmed 3 months after standard treatment with tiotropium in newly diagnosed COPD
patients.
Results: COPD prevalence varied substantially between 19.8% (LLN-COPD) and 32.1% (GOLD-COPD).
Twenty-three of 60 patients (38.3%) with GOLD-COPD were potentially misclassiﬁed as having COPD
(FEV1/FVC < 0.7 but > LLN). In contrast to patients with LLN-COPD, potentially misclassiﬁed patients did
not differ signiﬁcantly from those without COPD regarding respiratory symptoms and risk factors
for COPD.
Conclusions: One ﬁfth, rather than one third, of the patients with chronic HF had concomitant COPD using
the LLN instead of the ﬁxed ratio. LLN may identify clinically more important COPD than a ﬁxed ratio
of 0.7.
 2013 Elsevier Inc. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) frequently co-
exists with heart failure (HF), leading to poor prognosis as well as
diagnostic and therapeutic challenges.1 However, estimates of
COPD prevalence in patients with HFwith reduced or preserved leftactivity; ACE-I, angiotensin-
tor blocker; ATS/ERS, Amer-
MI, body mass index; CABG,
ctive pulmonary disease; CRT,
ers; FEV1/FVC, ratio of forced
rmer smokers; GOLD, Global
eart failure; ICD, implantable
LVEF, left ventricular ejection
LHFQ, Minnesota Living with
l Research Council dyspnea
B natriuretic peptide; NYHA,
nary intervention; PFT, pul-
All rights reserved.ventricular ejection fraction (LVEF) vary substantially between 9%
and 52%, depending on study design, population (age, gender,
smoking habits, inpatients versus outpatients, acute versus chronic
HF, primary, secondary, or tertiary care), and diagnostic criteria.1
Although spirometry is considered to be the gold standard for the
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spirometry is used, in general there is still no consensus on how to
deﬁne COPD.8e11 The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines recommend the use of a ﬁxed ratio of
forced expiratory volume in 1 s to forced vital capacity (FEV1/
FVC) < 0.70 for the sake of simplicity.2 However, a growing body of
literature indicates that considering the physiological decline of the
FEV1/FVC ratio with age the use of a ﬁxed ratio may lead to over-
diagnosis of COPD in elderly subjects12e19 and underdiagnosis of
COPD in young adults.15e17,20 Therefore, to avoid misclassiﬁcation,
the American Thoracic Society/European Respiratory Society (ATS/
ERS) recommends the use of statistically derived lower limit of
normal (LLN) values for FEV1/VC that are based on the normal
distribution and that classify the bottom 5% of the healthy popu-
lation as abnormal.21 This is particularly important in patients with
HF, given that HF is most prevalent among elderly individuals.22
Thus, a COPD prevalence of 30e44% may have been over-
estimated in prior studies that used a ﬁxed ratio of 0.7 to deﬁne
COPD in patients with HF.3e7 Subsequently, an incorrect diagnosis
of COPD may result in unnecessary treatment for COPD and
undertreatment with beta-blockers, with possible adverse health
effects.8,23,24
Although population-based studies have shown that the appli-
cation of different criteria to deﬁne airﬂow obstruction dramati-
cally changes the prevalence of COPD,18,25e30 it is less well
understood to what extent this occurs in patients with chronic
HF.6,7 Therefore, the primary aim of this study was to determine
COPD prevalence according to two deﬁnitions of airﬂow obstruc-
tion (FEV1/FVC < 0.70 versus FEV1/FVC < LLN) in outpatients with
stable chronic HF with left ventricular systolic dysfunction (LVSD).
The secondary aim of this study was to determine whether patients
potentially misclassiﬁed as having COPD (FEV1/FVC < 0.7
but > LLN) had clinical features of COPD or those of the healthy
population.
Methods
Study design and participants
All patients visiting two outpatient cardiology departments of a
large general hospital in The Netherlands were screened for in-
clusion in this prospective observational study between October
2009 and December 2010. In addition, existing patient lists were
used to ensure that the majority of the HF population had been
examined for eligibility. Inclusion criteria were stable chronic HF
with LVSD, i.e., LVEF < 40%, without pulmonary congestion, New
York Heart Association (NYHA) class IeIV, and age  18 years.
Chronic HF was deﬁned according to the European Society of Car-
diology guidelines.22 Echocardiography was performed in patients
without a recent (6 months) echocardiography to conﬁrm per-
sisting LVSD. Patients were classiﬁed as having stable HF in the
absence of hospitalization due to progression of HF within
3 months, change in diuretics within 1 month, 3% or more weight
gainwithin 3 days, andmore than 50% increase of N-terminal pro-B
natriuretic peptide (NT-pro-BNP) within 1 month when the base-
line NT-pro-BNPwas 100 pmol/L or higher ormore than 100 pmol/L
increase of NT-pro-BNP within 1 month when the baseline NT-pro-
BNP was below 100 pmol/L.31 Pulmonary congestionwas evaluated
on standard posterioreanterior and lateral chest radiographs
for the presence or absence of alveolar edema, pleural effusion,
Kerley-B lines, and/or the redistribution of pulmonary blood ﬂow
by independent radiologists who qualitatively assessed the chest
radiographs with an overall clinical impression. Patients who were
not able to cooperate or undergo spirometry or who had asthma
according to their medical chart were excluded. Other exclusioncriteria were malignancy with a poor prognosis (survival < 6
months) and participation in another study. Patients who had been
hospitalized in the pulmonary department in the past 6 weeks
were included 6 weeks after discharge to ensure that their pul-
monary function was stable at the time of spirometry testing.
In conformity with the ethical guidelines of the 1975 Declara-
tion of Helsinki, this study was conducted with the approval of the
regional Research Ethics Committee Arnhem-Nijmegen in The
Netherlands (2009/101, NL27798.091.09, ClinicalTrials.gov Identi-
ﬁer NCT01429376). All patients gave written informed consent.
Measurements and data collection
At baseline, a ﬁrst blood sample was taken for the measurement
of NT-pro-BNP according to standard methods used in the hospital
laboratory. Onemonth later, the participants visited the hospital for
an interview with the investigator and several examinations,
including height and weight measurement, spirometry, and a chest
radiograph. In addition, a second blood sample (NT-pro-BNP) was
taken to determine the stability of HF. A 10-point Borg score32 was
used to evaluate dyspnea at rest. Additional data were collected
from medical records and personal interviews. Arterial blood gas
analysis was performed on patients with severe airﬂow obstruction
to determine whether they had chronic respiratory failure.2
Patients with newly diagnosed COPD according to either deﬁ-
nition were followed up 3 months after standard treatment for
COPD with once-daily 18 mg tiotropium. A third blood sample
(NT-pro-BNP) was taken, and spirometry was repeated to conﬁrm
persistent airﬂow obstruction characteristic of COPD in an attempt
to exclude asthma as much as possible. Thus only patients with
persistent airﬂow obstruction on 3 months of follow-up were
classiﬁed as having COPD.
Spirometry testing
Spirometry (MasterLab Pro; Jaeger; Würzburg, Germany) was
performed by trained and certiﬁed operators using standard tech-
niques and according to ERS standards for acceptability and
reproducibility.33 The reference values of the European Community
for Coal and Steel were used.33 Subjects with airﬂow obstruction
according to either deﬁnition underwent post-bronchodilator
spirometry 30 min after inhalation of four doses of 100 mg aero-
solized salbutamol and four doses of 20 mg aerosolized ipratropium
via Volumatic spacer. Participants were instructed not to take
bronchodilators 6e24 h before the tests, depending on the type of
bronchodilator used. At follow-up, salbutamol and ipratropium
were used, as previously described, when patients discontinued the
use of tiotropium >24 h prior to spirometry. Care was taken to
match the timing of the second spirometry testing to the ﬁrst to
reduce variations that may occur over a 24-h period.
Deﬁnitions
COPD was deﬁned according to two criteria: post-bronchodilator
FEV1/FVC < 0.7 (GOLD-COPD)2 and post-bronchodilator FEV1/
FVC < LLN (LLN-COPD).21 LLN was regarded as the lower ﬁfth
percentile of the frequency distribution of a healthy reference pop-
ulation and was calculated by subtracting 1.64 times the residual
standard deviation from the predicted value. The investigator
who identiﬁed the GOLD or LLN criteria was not blinded to the
other rating.
Smoking status was deﬁned as never (<100 cigarettes in a life-
time), former (3 months ago), or current smoker (<3 months).
Smoking pack-years (PY) were based only on the tobacco cigarette
Screened for inclusion
n = 2001
Initial inclusion
n = 337
1131 Not meeting inclusion criteria
131   Met exclusion criteria
91 Not able to cooperate or 
undergo spirometry
36 Asthma bronchiale
3   Participation in another study
1   Malignancy with bad prognosis
311   Refused informed consent
37     Other hospital, no contact 
54     Deceased
38 Withdrew informed consent  
112    Excluded:           
- 47 Unstable and/or congested chronic HF
- 44 Improved LVEF
- 10 No reliable PFT
- 4   Asthma bronchiale
- 4   LVSD without chronic HF
- 2   Did not cooperate
- 1   Deceased
Final inclusion
n = 187
Fig. 1. Flow-diagram of screening and ﬁnal inclusion of study participants. HF, heart
failure; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunc-
tion; PFT, pulmonary function tests.
Table 1
Characteristics of patients.
All (n ¼ 187)
Age, years 69  10
Male sex, n (%) 146 (78)
BMI, kg/m2 28  5
LVEF, % 29  7
NYHA IeII, % 164 (88)
NYHA IIIeIV, % 23 (12)
Ischemic etiology 110 (59)
Co-morbidity, n (%)
Myocardial infarction 109 (58)
PCI/CABG 76 (41)
CRT/ICD 64 (34)
Atrial ﬁbrillation 54 (29)
Hypertension 80 (43)
Diabetes mellitus 46 (25)
Medication, n (%)
ACE-I/ARB 174 (93)
b-blockers 172 (92)
Diuretics 159 (85)
Aldosterone-antagonists 65 (35)
Laboratory data
NT-pro-BNP1, pmol/L 201  289
NT-pro-BNP2, pmol/L 198  308
Data are presented as the mean  SD and number (%). Laboratory data 1 and 2 refer
to the ﬁrst (at baseline) and second (1 month later) blood samples, respectively.
ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker;
BMI, body mass index; CRT/ICD, cardiac resynchronization therapy/implantable
cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; NT-pro-BNP, N-
terminal pro-B natriuretic peptide; NYHA, New York Heart Association; PCI/CABG,
percutaneous coronary intervention/coronary artery bypass grafting.
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1 year.
Dyspneawas deﬁned as resting dyspnea or dyspnea at any level
of exertion, chronic cough as cough 3 months prior to the study,
chronic sputum production as the regular production of sputum for
3 months in 2 consecutive years, and aspeciﬁc bronchial hyperre-
activity (ABHR) as respiratory symptoms in response to perfumes,
the scent of baking or paint, fog, cold air, or temperature changes.
GOLD-COPD severity stagingwas determined on the basis of FEV1
percent predicted according to GOLD criteria: FEV180% predicted
(stage I, mild), 50%  FEV1 < 80% predicted (stage II, moderate),
30%  FEV1 < 50% predicted (stage III, severe), and FEV1 < 30%
predicted or FEV1 < 50% predicted plus chronic respiratory failure
(stage IV, very severe).2 LLN-COPD severity staging was determined
on the basis of FEV1 percent predicted according to ATS/
ERS criteria: FEV1  70% predicted (mild), FEV1 60e69%
predicted (moderate), FEV1 50e59% predicted (moderately severe),
FEV1 35e49% predicted (severe), and FEV1 < 35% predicted
(very severe).
Statistical analysis
Descriptive data are presented as the mean  SD or as a num-
ber (%). Baseline characteristics of patients with and without
GOLD-COPD were compared using an independent t-test or a
ManneWhitney U test for continuous variables and a Chi-square
or Fisher’s exact test for categorical variables, as appropriate.
Differences in continuous variables between three groups of pa-
tients (patients with LLN-COPD, patients with potentially mis-
classiﬁed COPD [FEV1/FVC < 0.7 but > LLN], and patients without
COPD) were examined with independent analysis of variance.
Post hoc analyses were performed using Fisher’s LSD test, and a
GameseHowell test was used when the assumption of homoge-
neity of variance was not met. Log transformation was applied to
achieve normal distribution when the assumption of normal dis-
tribution was not met. Differences in categorical variables between
the aforementioned three groups of patients were analyzed with a
chi-square test, and the Bonferroni correction was used to control
for type I errors. Statistical analyses were performed using the
Statistical Package for Social Science version 15.0. All statistical tests
were two-sided, and a p-value <0.05 was considered signiﬁcant.
Results
Patient characteristics
A cohort of 337 patients with chronic HF was initially included
in this study. Thirty-eight patients withdrew informed consent, and
65 patients were excluded for several reasons, as speciﬁed in Fig. 1.
The remaining 234 patients were included in the study, of whom
187 had stable chronic HF without signs of congestion on chest
radiograph. Table 1 shows the characteristics of these patients. The
mean agewas 69 10 years, themeanwas LVEF 29 7%, and 78% of
participants were male. The majority of patients had NYHA class II
(72%). Almost 60% had an ischemic etiology of HF. Other causes of
HF were idiopathic causes (24%), hypertension (6%), valve disease
(6%), tachycardiomyopathy (3%), and other causes (2%). Most pa-
tients were former or current smokers (83%) and reported symp-
toms of dyspnea (82%) (Table 2). Other respiratory symptoms were
less common.
COPD prevalence
COPD prevalence varied substantially according to the deﬁnition
used, from 19.8% (LLN-COPD) to 32.1% (GOLD-COPD), after 3 monthsof follow-up (Fig. 2A). GOLD-COPD prevalence tended to be higher in
men thanwomen (35.6% versus 19.5%, p ¼ 0.051). The prevalence of
LLN-COPD was not signiﬁcantly different between men and women
(21.9% versus 12.2%, p ¼ 0.167). The lack of statistical signiﬁcance
when comparing COPD prevalence according to gender is likely a
function of sample size. Regardless of the deﬁnition used, the
prevalence of COPD was higher in current and former smokers than
in non-smokers (GOLD-COPD: 43.5%, 35.6%, and 9.4%, respectively,
overall p ¼ 0.008; LLN-COPD: 26.1%, 23.5%, and 0%, respectively,
overall p ¼ 0.008), with no signiﬁcant differences between current
and former smokers (Fig. 2A). Interestingly, none of the non-smokers
had COPD according to the LLN, while 3 of 32 (9.4%) non-smokers
were diagnosed with COPD using the ﬁxed ratio. None of the 9
Table 2
Comparison of GOLD-COPD, LLN-COPD, and potentially misclassiﬁed COPD patients with patients without COPD.
All (n ¼ 187) GOLD-COPD
(n ¼ 60)
LLN-COPD
(n ¼ 37)
Potentially misclassiﬁed:
<0.7 but >LLN (n ¼ 23)
No COPD
(n ¼ 127)
Age, years 69  10 70  9 70  9 71  9 68  11
Male sex, n (%) 146 (78) 52 (87) 32 (86) 20 (87) 94 (74)
Smoking history, n (%)
Non-smoker 32 (17) 3 (5)a 0 (0)a 3 (13) 29 (23)
Current/former smoker 155 (83) 57 (95)a 37 (100)a 20 (87) 98 (77)
PY, years 24  24 30  28a 33  27a 24  29 21  21
Symptoms, n (%)
Cough 67 (36) 29 (48)a 19 (51)a 10 (43) 38 (30)
Sputum 43 (23) 17 (28) 13 (35) 4 (17) 26 (20)
Dyspnea 153 (82) 52 (87) 32 (86) 20 (87) 101 (80)
ABHR 55 (29) 26 (43)a 21 (57)a,b 5 (22) 29 (23)
Borg dyspnea scale 0.9  1.2 1.1  1.3a 1.5  1.4a,b 0.6  1.0 0.8  1.2
Respiratory symptoms or pneumonia in childhood 19 (10) 7 (12) 6 (16) 1 (4) 12 (9)
Family history of asthma or COPD 48 (26) 19 (32) 16 (43)a,b 3 (13) 29 (23)
Spirometry
FEV1, L 2.5  0.8 2.1  0.7a 1.9  0.7a,b 2.4  0.6 2.7  0.8
FEV1, % predicted 88  21 72  22a 64  18a,b 85  22 96  15
FVC, L 3.7  1.0 3.8  1.0 3.8  1.0 3.8  1.0 3.7  1.0
FVC, % predicted 102  19 101  23 100  24 102  24 102  17
FEV1/FVC, % 68  11 55  10a 49  8a,b 64  3a 74  5
Data are presented as the mean  SD and number (%). Only pre-bronchodilator lung function test results are presented to facilitate the comparison between groups.
ABHR, aspeciﬁc bronchial hyperreactivity; COPD, chronic obstructive pulmonary disease; FEV1/FVC, ratio of forced expiratory volume in 1 s to forced vital capacity; GOLD,
Global Initiative for Chronic Obstructive Lung Disease; LLN, lower limit of normal; PY, pack-years.
a p-value <0.05 compared with patients without COPD.
b p-value <0.05, LLN-COPD compared with potentially misclassiﬁed COPD patients.
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using either deﬁnition. COPD prevalence according to the other age
categories is shown in Fig. 2B. Most patients had mild to moderately
severe COPD, while only a minority had severe or very severe COPD
(Table 3).
Twenty-three of 60 patients (38.3%) with GOLD-COPD were
potentially misclassiﬁed as having COPD. The majority of these pa-
tients had only mild COPD (GOLD stage I: 61% versus 38%, p¼ 0.082)
in contrast to patients with true COPD (FEV1/FVC < 0.7 and <LLN)
who had more severe disease. These potentially misclassiﬁed pa-
tients did not differ signiﬁcantly from patients without COPD, except
for a lower ratio of FEV1/FVC (64  3% versus 74  5%, p < 0.001)
(Table 2). On the other hand, patients with LLN-COPD did in fact
show signiﬁcant differences compared with patients without COPD:
they smokedmore (33 27 PY versus 21 21 PY, p< 0.001; current/
former smokers 100% versus 77%, p ¼ 0.001); they had more
symptoms of cough (51% versus 30%, p ¼ 0.016), Borg dyspnea
(1.5  1.4 versus 0.8  1.2, p ¼ 0.026) and ABHR (57% versus 23%,
p < 0.001); they reported a family history of asthma or COPD more
often (43% versus 23%, p ¼ 0.014); and they had a lower FEV1
(64 18% predicted versus 96 15% predicted, p< 0.001) and FEV1/
FVC ratio (49  8% versus 74  5%, p < 0.001) (Table 2). Moreover,
LLN-COPD patients also differed signiﬁcantly from potentially mis-
classiﬁed patients: they had more symptoms of Borg dyspnea
(1.5  1.4 versus 0.6  1.0, p ¼ 0.019) and ABHR (57% versus 22%,
p ¼ 0.008); more frequently, they had a family history of asthma or
COPD (43% versus 13%, p ¼ 0.014); they had a lower FEV1 (64  18%
predicted versus 85  22% predicted, p ¼ 0.010) and FEV1/FVC ratio
(49  8% versus 64  3%, p ¼ 0.002); and they tended to be more
likely current/former smokers (100% versus 87%, p ¼ 0.052).
Patients with GOLD-COPD differed signiﬁcantly from patients
without COPD on corresponding variables as those with LLN-COPD,
except for one variable; in contrast to patients with LLN-COPD who
signiﬁcantly more often had a family history of asthma or COPD
when compared with those without COPD, this was not true for
patients with GOLD-COPD (Table 2).
Thirty-four of 60 patients (56.7%) with GOLD-COPD had previ-
ously been diagnosed with obstructive lung disease, comparedwith 25 of 37 patients (67.6%) with LLN-COPD. On the other hand,
16 of 50 (32.0%) patients with a history of obstructive lung disease
did not have GOLD-COPD according to their spirometry. The cor-
responding ﬁgure was 25/50 (50.0%) for LLN-COPD.
Discussion
This is one of the few studies to determine the prevalence of
COPD in patients with chronic HF using two deﬁnitions of COPD,
namely, the ﬁxed ratio of 0.7 and the LLN.6,7 Our results support
previous ﬁndings that COPD frequently coexists with chronic HF.3e7
However, the exact deﬁnition of airﬂow obstruction alters COPD
prevalence substantially; one ﬁfth, rather than one third, of the
patients with chronic HF had concomitant COPD using the LLN
instead of the ﬁxed ratio. LLN may identify clinically more impor-
tant COPD than a ﬁxed ratio of 0.7 as patients who were potentially
misclassiﬁed as having COPD, in contrast to patients with
LLN-COPD, did not differ signiﬁcantly from those without COPD in
terms of respiratory symptoms and risk factors for COPD.
As expected, using the ﬁxed ratio of 0.7 resulted in a consider-
ably higher prevalence of COPD compared with using the LLN
(32.1% versus 19.8%, respectively). This ﬁnding is in line with the
results of Steinacher et al7 who reported COPD prevalence rates of
43.8% according to the GOLD criteria (ﬁxed ratio) and 24.7% ac-
cording to ATS/ERS criteria (LLN) in 89 outpatients with stable
chronic HF. However, this ﬁnding was not as well supported in
another study of 118 elderly (65 years) patients with stable
chronic HF, most likely because of the selection of patients
with 10 PY (COPD prevalence 30.5% versus 28.8%).6
Given the physiological decline of the FEV1/FVC ratio with age,
using the ﬁxed ratio instead of the LLN may result in a diagnosis of
COPD in elderly individuals who may not actually have COPD12e19
which is of particular concern in patients with HF, given that
most patients affected by HF are elderly22 (80.2% of the patients in
the current study were older than 60 years). Almost 40% of the
patients who were diagnosed with GOLD-COPD based on spirom-
etry were potentially misclassiﬁed as having COPD because their
FEV1/FVC ratio was above the LLN.
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Fig. 2. COPD prevalence as deﬁned by two spirometric criteria and according to (A)
gender and smoking status, and (B) age categories. COPD, chronic obstructive pul-
monary disease; CS, current smokers; FS, former smokers; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; LLN, lower limit of normal; NS, non-smokers.
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single test. Clinical ﬁndings, including history and exposure to risk
factors, can facilitate the diagnosis of COPD,2 and the physician
ultimately determines the medical signiﬁcance of an abnormal
spirometric value based on these clinical ﬁndings. However, these
decisions are more complicated in patients with HF due to overlap
in signs and symptoms as well as risk factors,1 which explains, at
least in part, the considerable over and underdiagnosis of COPD
observed in this study. The majority (74%) of patients with poten-
tially misclassiﬁed COPD had respiratory symptoms (dyspnea,
cough, and/or sputum production) combined with a smokingTable 3
Distribution of COPD patients according to GOLD and ATS/ERS severity stages.
Severity class GOLD-COPD (n ¼ 60)
All (n ¼ 60) Potentially
<0.7 but >
Mild, n (%) 28 (47) 14 (61)
Moderate, n (%) 24 (40) 7 (30)
Moderately severe, n (%) e e
Severe, n (%) 5 (8) 2 (9)
Very severe, n (%) 3 (5) 0 (0)
Data are presented as number (%).
ATS/ERS, American Thoracic Society/European Respiratory Society. Other abbreviations ahistory (current or former smoker), whichwas also true for patients
without COPD, of whom 64% had respiratory symptoms combined
with a smoking history. Subsequently, an incorrect diagnosis of
COPD and unnecessary treatment as a consequence may be asso-
ciated with side-effects of pharmacological interventions,34 espe-
cially in elderly patients with HF who usually have several
co-morbidities and are prone to polypharmacy. In addition, con-
cerns have been raised regarding the cardiovascular safety proﬁle
of bronchodilators. Beta-agonists have been reported to increase
the risk for adverse cardiovascular events in patients with
obstructive airway disease, with a signiﬁcant increase in sinus
tachycardia and a non-signiﬁcant trend toward an increase inmajor
cardiovascular events, including ventricular tachycardia, atrial
ﬁbrillation, syncope, congestive heart failure, myocardial infarction,
cardiac arrest, and sudden death.35 Moreover, observational studies
have shown worse outcomes with bronchodilator use in patients
with HF, including increased risk of HF hospitalization, increased
mortality rates, in-hospital mechanical ventilation, intravenous
vasodilator use, and major cardiovascular events associated with
the use of beta-agonists, although further investigation is war-
ranted.23,36 Furthermore, inhaled anticholinergics have been re-
ported to be associated with an increased risk of cardiovascular
death, myocardial infarction, or stroke among patients with
COPD,37 although recently reassuring cardiovascular safety data
have been reported on the long-acting anticholinergic bronchodi-
lator tiotropium (HandiHaler).38,39 Nevertheless, bronchodilators,
in particular beta-agonists, must be used with caution in patients
with underlying cardiac condition such as HF.
Aside from the possible side-effects and adverse cardiovascular
events associated with pharmacological treatment for COPD,
incorrect diagnosis and interventions for COPD may have a
considerable psychological impact on the subject and his/her
family and may cause an unnecessary ﬁnancial burden on society.8
Furthermore, incorrect diagnosis of COPD may lead to undertreat-
ment with life-saving beta-blockers.23,24 Therefore, there is a need
for clear diagnostic criteria for COPD to avoid diagnostic confusion,
incorrect diagnosis, and inappropriate treatment.
Unfortunately, there is no gold standard for the diagnosis of
COPD. The hallmark of the disease is the presence of airﬂow limi-
tation that is not fully reversible and is usually progressive in na-
ture.2 However, there is no consensus on the spirometric criteria for
the diagnosis of COPD.8e11 Considering the physiological decline of
the FEV1/FVC ratio with age, the application of statistically derived
LLN values for FEV1/FVC that are based on the normal distribution
and that classify the bottom 5% of the healthy population as
abnormal should be preferred to avoid overdiagnosis of COPD in
elderly subjects12e19 and underdiagnosis in young adults.15e17,20
However, little is known about the clinical impact of these
different criteria and contrasting results have been re-
ported.12,20,40e47 More longitudinal studies are needed to deter-
mine which criterion is better and clinically more relevant.48LLN-COPD
(n ¼ 37)
misclassiﬁed:
LLN (n ¼ 23)
True COPD: <0.7
and <LLN (n ¼ 37)
14 (38) 21 (57)
17 (46) 7 (19)
e 4 (11)
3 (8) 3 (8)
3 (8) 2 (5)
re identical to those in the Table 2 legend.
A.G. Minasian et al. / Heart & Lung 42 (2013) 365e371370In the current study, patients whowere potentially misclassiﬁed
as having COPD did not differ signiﬁcantly from those without
COPD in terms of respiratory symptoms and risk factors for COPD.
On the contrary, patients with LLN-COPD did in fact show signiﬁ-
cant differences when they were compared with patients without
COPD in terms of respiratory symptoms (cough, Borg dyspnea, and
ABHR) and risk factors for COPD (smoking history and a family
history of asthma or COPD). Moreover, patients with LLN-COPD
more frequently had respiratory symptoms (Borg dyspnea and
ABHR) and a family history of asthma or COPD compared with
patients with potentially misclassiﬁed COPD, and they more
frequently tended to be current or former smokers. Although this
study is not longitudinal in nature, these ﬁndings imply that using
the LLN may identify clinically more important COPD than a ﬁxed
ratio of 0.7. In support of this implication, 67.6% of the patients with
LLN-COPD were previously diagnosed with obstructive lung dis-
ease, compared to only 39.1% of patients with potentially mis-
classiﬁed COPD.
A limitation of the LLN criterion is its dependence on the pre-
diction equations and on the reference population from which the
prediction equations have been drawn. In the USA, ethnically
appropriate National Health and Nutrition Examination Survey
(NHANES) III reference equations are recommended for those aged
8e80 years.49 In Europe, the combined reference equations pub-
lished in the 1993 ERS statement are often used for people aged
18e70 years, with a height range of 155e195 cm inmales, and 145e
180 cm in females.33 Recent ATS/ERS guidelines do not recommend
any speciﬁc set of equations to be used in Europe, but they do
suggest the need for a new Europe-wide study to derive updated
reference equations.21 Recently, multi-ethnic spirometric predic-
tion equations for the 3e95 years age range that include appro-
priate age-dependent lower limits of normal and that can be
applied globally have become available.50
A limitation to our study is the lack of follow-up to determine
how the different spirometric deﬁnitions of COPD relate to out-
comes such as pulmonary function decline, hospitalization, and
mortality. Furthermore, it is important to realize that the preva-
lence of COPD found in this study may not be applicable to all pa-
tients with chronic HF because we did not include patients with
preserved systolic function. Additionally, patients with more severe
HF could have been under-represented in this study because of
their inability to participate.
Clinical implications and implications for future research
Despite these limitations, our ﬁndings have potential clinical
implications and implications for future research. The results stress
the need for a clear deﬁnition of COPD, especially in patients with
HF in whom the diagnosis of COPD is already complicated due to
overlap in signs, symptoms, and risk factors and who are prone to
the adverse effects of pharmacological treatment for COPD. Using
the LLN results in considerably lower COPD prevalence rates when
compared with using the ﬁxed ratio of 0.7: one ﬁfth, rather than
one third, of the patients with chronic HF had concomitant COPD.
Moreover, LLN may identify clinically more important COPD than
the ﬁxed ratio. More longitudinal studies are needed to determine
which criterion is better and clinically more relevant in terms of
morbidity (symptoms, exercise tolerance, health-related quality of
life, exacerbations, hospitalization, pulmonary function decline, use
of health recourses, systemic effects such as co-morbidities and
systemic biomarkers) and mortality. Finally, future research should
focus on the clinical beneﬁt of treating COPD according to either
deﬁnition in patients with HF and the cardiovascular safety proﬁle
of bronchodilators, especially in patients with underlying cardiac
condition such as HF.Acknowledgments
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